Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-25-014320
Filing Date
2025-02-14
Accepted
2025-02-14 16:30:29
Documents
44
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0230776-10q_citius.htm   iXBRL 10-Q 492485
2 CERTIFICATION ea023077601ex31-1_citius.htm EX-31.1 9920
3 CERTIFICATION ea023077601ex31-2_citius.htm EX-31.2 10188
4 CERTIFICATION ea023077601ex32-1_citius.htm EX-32.1 4246
  Complete submission text file 0001213900-25-014320.txt   2437303

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE ctor-20241231.xsd EX-101.SCH 20981
6 XBRL CALCULATION FILE ctor-20241231_cal.xml EX-101.CAL 16509
7 XBRL DEFINITION FILE ctor-20241231_def.xml EX-101.DEF 100440
8 XBRL LABEL FILE ctor-20241231_lab.xml EX-101.LAB 188439
9 XBRL PRESENTATION FILE ctor-20241231_pre.xml EX-101.PRE 109779
46 EXTRACTED XBRL INSTANCE DOCUMENT ea0230776-10q_citius_htm.xml XML 135258
Mailing Address 420 LEXINGTON AVE, SUITE 2446 NEW YORK NY 10017
Business Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016 (908) 967-6677
CITIUS ONCOLOGY, INC. (Filer) CIK: 0001851484 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 0930
Type: 10-Q | Act: 34 | File No.: 001-41534 | Film No.: 25629662
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)